Preparation & Measurement Guide

NAD+ 500mg Dosage Protocol

Preparation, measurement, commonly documented protocol ranges, and storage for a NAD+ 500mg vial.

Research use only Educational summary of a commonly documented convention. Not approved for human use.
Vial Size NAD+ 500mg
Preparation 2mL bacteriostatic water
Concentration 250mg/mL after preparation
Documented Convention 50-100mg once daily

1. Preparation and Measurement

NAD+ 500mg With 2mL of Diluent

Add 2mL of bacteriostatic water to the vial. The resulting concentration is 250mg/mL. On a U-100 syringe, each unit contains 2.5mg.

500mg / 2mL = 250mg/mL
1 U-100 unit = 0.01mL = 2.5mg

Preparation

  1. Draw 2mL of bacteriostatic water using sterile equipment.
  2. Let the liquid run slowly down the inside wall of the vial.
  3. Gently swirl until dissolved. Do not shake.
  4. Label with the preparation date and refrigerate.

Check the calculation with the peptide calculator.

2. Commonly Documented Schedule

Route commonly described: subcutaneous in circulated vial protocols. Frequency: once daily.

Period Documented amount Measurement
Week 1 50mg once daily 0.2mL / 20 units
Week 2 75mg once daily 0.3mL / 30 units
Weeks 3-4 100mg once daily 0.4mL / 40 units

Vial estimate: One 500mg vial contains approximately 10 administrations at the first listed amount or 5 at the final listed amount.

Practical Notes

  • The table applies only to this vial prepared with exactly 2mL.
  • Record the amount, date, and preparation used.

3. Supplies Needed

  • NAD+ 500mg vial.
  • 2mL of bacteriostatic water per vial.
  • Sterile U-100 syringes.
  • Alcohol swabs.
  • Sharps container.

4. Storage and Handling

  • Keep unopened vials cool, dry, dark, and protected from moisture.
  • After preparation, refrigerate at 2-8 degrees C.
  • Protect from light and avoid repeated freeze-thaw cycles.
  • Do not use material with particles, discoloration, or a damaged seal.

5. Research Context

NAD+ is a central metabolic cofactor. Direct human studies have primarily examined intravenous infusion and metabolite handling, not the subcutaneous convention shown here.

Evidence for injected NAD+ remains limited, and published intravenous findings cannot validate a different route, concentration, or schedule.

Primary Research and Regulatory References

  1. Human intravenous NAD+ metabolome pilot study
  2. Intravenous NAD+ tolerability pilot study
  3. NAD+ metabolism and aging review

Research Materials

Review NAD+ 500mg Product Information

← Back to Dosage Protocols

Research-use disclaimer: NAD+ 500mg products sold by Vialcrest are intended strictly for laboratory research. They are not intended for human consumption, injection, therapeutic use, medical use, diagnostic use, or veterinary use. This article documents how a commonly circulated or published convention is described for educational comparison. It does not endorse that convention, establish safety or efficacy, or provide medical advice.